[Integrating new migraine treatments into clinical practice. Part 2 : preventive treatment].

Migraine is the most common neurological disorder and can be very debilitating. While traditional (and older) oral preventive treatments have helped numerous patients to date, their therapeutic efficacy is often low, and adverse event profiles are troublesome. However, the coupled progress of biochemistry and molecular biology as well as the application of advanced drug design methods have led to a therapeutic renewal with, in particular, the advent of monoclonal antibodies blocking CGRP («Calcitonin Gene- Related-Peptide») transmission. We provide an overview of the preventive pharmacologic options with both older oral treatments and new ones such as botulinum toxin and the newly marketed CGRP monoclonal antibodies. The latter seem particularly interesting because they have an effectiveness at least equivalent to most oral treatments with much better tolerance and compliance. Unfortunately, their very high cost confines them to a fourth line of therapy in Belgium, a disappointment for both specialists in migraine therapy and patients who suffer from frequent migraine crisis. We finally propose a rational (and Belgian) pharmacological approach of migraine preventive treatment.